Down-regulating humoral immune responses: Implications for organ transplantation

Transplantation

Volumn 97, Issue 3, 2014, Pages 247-257

  Stegall, Mark D ^a   Moore, Natalie ^a   Taner, Timucin ^b   Li, Han ^b   Dean, Patrick G ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Alloantibody; Antibody mediated rejection; Complement; Humoral immunity; Immunoregulation; Kidney transplantation; Memory B cells; Plasma cells; Tolerance

Indexed keywords

ANIMALS; ANTIBODIES; APOPTOSIS; B-LYMPHOCYTES; BONE MARROW CELLS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GRAFT REJECTION; HUMANS; IMMUNE TOLERANCE; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; ISOANTIBODIES; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOID TISSUE; MICE; ORGAN TRANSPLANTATION; PLASMA CELLS;

EID: 84894025549     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a72115     Document Type: Review

References (81)

1. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365: 318.
2. Bentall A, Cornell LD, Gloor JM, et al. Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013; 13: 76.
3. Taner T, Gandhi MJ, Sanderson SO, et al. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12: 1504.
4. Daly RC, Topilsky Y, Joyce L, et al. Combined heart and liver transplantation: protection of the cardiac graft from antibody rejection by initial liver implantation. Transplantation 2013; 95: e2.
5. Ciurea SO, Thall PF, Wang X, et al. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood 2011; 118: 5957.
6. von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010; 11: 14.
7. Nemazee D. Does immunological tolerance explain the waste in the B-lymphocyte immune system? Experiment and theory. Ann N Y Acad Sci 1995; 764:397.
8. Zotos D, Tarlinton DM. Determining germinal centre B cell fate. Trends Immunol 2012; 33: 281.
9. Phan TG, Paus D, Chan TD, et al. High affinity germinal center B cells are actively selected into the plasma cell compartment. J Exp Med 2006; 203: 2419.
10. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157.
11. Zachary AA, Kopchaliiska D, Montgomery RA, et al. HLA-specific B cells: II. Application to transplantation. Transplantation 2007; 83: 989.
12. Everly MJ, Rebellato LM, Haisch CE, et al. Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation 2013; 95: 410.
13. Pestana JO, Grinyo JM, Vanrenterghem Y, et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belateacept versus cyclo-sporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630.
14. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89: 277.
15. Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555.
16. Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody mediated rejection. Am J Transplant 2009; 9: 231.
17. Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998; 10: 252.
18. Manz RA, Hauser AE, Hiepe F, et al. Maintenance of serum antibody levels. Annu Rev Immunol 2005; 23: 367.
19. Fairfax KA, Kallies A, Nutt SL, et al. Plasma cell development: from B cell subsets to long-term survival niches. Semin Immunol 2008; 20: 49.
20. Tangye SG. Staying alive: regulation of plasma cell survival. Trends Immunol 2011; 32: 595.
21. De la Torre I, Leandro JM, Valor L, et al. Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics. Rheumatology 2012; 12: 833.
22. Vieira CA, Agarwal A, Book BK, et al. Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: safety, pharmacodynamics, and pharmacokinetics. Transplantation 2004; 77: 542.
23. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903.
24. Minges-Wold HA, Underhill GH, Kansas GS, et al. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol 2002; 169: 4213.
25. Chu VT, Frohlich A, Steinhauser G, et al. Eosinophils are required for the maintenance of plasma cells in bone marrow. Nat Immunol 2011; 12: 15.
26. Winter O, Moser K, Mohr E, et al. Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow. Blood 2010; 116: 1867.
27. Balazs M, Martin F, Zhou T, et al. Blood dendritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002; 17: 341.
28. Rodriguez Gomez M, Talke Y, Goebel N, et al. Basophils support the survival of plasma cells in mice. J Immunol 2010; 185: 7180.
29. Mohr E, Serre K, Manz RA, et al. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microen-vironments where plasmablasts mature. J Immunol 2009; 182: 2113.
30. Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood 2004; 103: 3148.
31. Carrington EM, Vikstrom IB, Light A, et al. BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proc Natl Acad Sci USA 2010; 107: 10967.
32. http://clinicaltrials.gov/ct2/show/NCT01025193.
33. Ramos EJ, Pollinger HS, Stegall MD, et al. The effect of desensitization protocols on human splenic B cells in vivo. Am J Transplant 2007; 7: 402.
34. Perry DK, Pollinger HS, Burns JM, et al. Two novel assays of antibody-secreting cells demonstrating resistance to desensitization with IVIG and rATG. Am J Transplant 2008; 8: 133.
35. Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9: 201.
36. Diwan TS, Raghavaiah S, Burns JM, et al. The impact of proteasome inhibition on alloantibody-producing plasma cells in vivo. Transplantation 2011; 91: 536.
37. Wahrmann M, Haidinger M, Körmöczi GF, et al. Effect of the pro-teasome inhibitor bortezomib on humoral immunity in two presen-sitized renal transplant candidates. Transplantation 2010; 89: 1385.
38. Sberro-Soussan R, Zuber J, Suberbielle-Boissel C, et al. Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies. Am J Transplant 2010; 10: 681.
39. Mateos MV, San Miguel JF. Bortezomib in multiple myeloma. Best Pract Res Clin Haematol 2007; 20: 701.
40. Richardson PG, Sonneveid P, Schuester MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487.
41. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010; 116: 679.
42. Markovina S, Callander NS, O'Connor SL, et al. Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NK-B activity in myeloma cells. Mol Cancer 2010; 9: 176.
43. Neyt K, Perros F, GeurtsvanKessel CH, et al. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol 2012; 33: 297.
44. Zarkhin V, Kambham N, Li L, et al. Characterization of intra-graft B cell during renal allograft rejection. Kidney Int 2008; 74: 664.
45. Marrari M, Duquesnoy RJ. Detection of donor-specific HLA antibodies before and after the removal of a rejected kidney transplant. Transplant Immunol 2010; 22: 105.
46. Zarkhin V, Chalasani G, Sarwal MM. The yin and yang of B cells in allograft rejection and tolerance. Transplant Rev 2010; 24: 67.
47. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14: 748.
48. Sicard A, Phares TW, Yu H, et al. The spleen is the major source of antidonor antibody-secreting cells in murine heart allograft recipients. Am J Transplant 2012; 12: 1708.
49. + B cells: memory B cells or "memory" B cells? J Immunol 2007; 179: 13.
50. Maurer D, Holter W, Majdic O, et al. CD27 expression by a distinct population of human B lymphocytes. Eur J Immunol 1990; 148: 3700.
51. Pescovitz MD, Torgerson TR, Ochs HD, et al. Effect of rituximab on human in vivo antibody immune responses. J Allergy Clin Immunol 2011; 128: 1295.
52. Nashi E, Wand YH, Diamond B. The role of B cells in lupus patho-genesis. Int J Biochem Cell Biol 2010; 42: 543.
53. + human circulating memory B cells and bone marrow plasma cells. Proc Natl Acad Sci 2011; 108: 18044.
54. Burns JM, Cornell LD, Perry DK, et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. Am J Transplant 2008; 8: 2684.
55. Mulder A, Eijsink C, Kardol MJ et al. Identification, isolation and culture of HLA-A2 specific B lymphocytes using MHC class I tetra-mers. J Immunol 2003; 171: 6599.
56. Zachary AA, Kopchaliiska D, Montgomery RA, et al. HLA-specific B cells. Method of their detection, quantification, and isolation using HLA tetramers. Transplantation 2007; 83: 982.
57. Han M, Rogers JA, Lavingia B, et al. Peripheral blood B cells producing donor-specific HLA antibodies. Hum Immunol 2009; 70: 29.
58. Heidt S, Roelen DL, de Vaal YJH, et al. A novel ELISPOT assay to quantify HLA-specific B cell in HLA-immunized individuals. Am J Transplant 2012; 12: 1469.
59. Vo AA, Peng A, Toyoda M, et al. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation. Transplantation 2010; 89: 1095.
60. Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant 2003; 3: 1017.
61. Montgomery RA, Zachary AA. Transplanting patients with a positive donor-specific crossmatch: a single center's perspective. Pediatr Transplant 2004; 8: 535.
62. Gloor JM, Winters JL, Cornell LD, et al. Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation. Am J Transplant 2010; 10: 582.
63. Stegall MD, Chedid MF, Cornell LD, et al. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012; 8: 670.
64. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405
65. U.S. National Library of Medicine. ClinicalTrials.gov. http://www. clinicaltrials.gov/ct2/show/NCT01399593 (2012).
66. Gordon RD, Fung JJ, Markus B, et al. The antibody crossmatch in liver transplantation. Surgery 1986; 100: 705.
67. Fung J, Makowka L, Tzakis A, et al. Combined liver-kidney transplantation: analysis of patients with preformed lymphocytotoxic antibodies. Transplant Proc 1988; 20: 88.
68. Hanish SI, Samaniego M, Mezrich JD, et al. Outcomes of simultaneous liver/kidney transplants are equivalent to kidney transplant alone: a preliminary report. Transplantation 2010; 90: 52.
69. Gugenheim J, Amorosa L, Gigou M, et al. Specific absorption of lymphocytotoxic alloantibodies by the liver in inbred rats. Transplantation 1990; 144: 309.
70. Ingelsten M, Karlsson-Parra A, Granqvist AB, et al. Postischemic inflammatory response in an auxiliary liver graft predicts renal graft outcome in sensitized patients. Transplantation 2011; 91: 888.
71. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transplant 2011; 11: 841.
72. Astarcioglu I, Cursio R, Reynes M, et al. Increased risk of antibody-mediated rejection of reduced-size liver allografts. J Surg Res 1999; 84: 258.
73. O'Leary JG, Gebel HM, Ruiz R, et al. Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant 2013; 4: 954.
74. Bluestone JA. Mechanisms of tolerance. Immunol Rev 2011; 241: 5.
75. Bluestone JA, Auchincloss H, Nepon GT, et al. The immune tolerance network at 10 years: tolerance research at the bedside. Nat Rev Immunol 2010; 10: 797.
76. Kawai T, Cosimi AB, Spikzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353.
77. Knechtle SJ, Pascual J, Bloom DD. Early and limited use of tacrolimus to avoid rejection in an alemtuzumab and sirolimus regimen for kidney transplantation: clinical results and immune monitoring. Am J Transplant 2009; 9: 1087.
78. Parsons RF, Vivek K, Redield RR, et al. B cell tolerance in transplantation: is repertoire remodeling the answer? Expert Rev Clin Immunol 2009; 5: 703.
79. Parsons RF, Vivek K, Redfield RR, et al. B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant Rev 2010; 24: 207.
80. Kennedy RB, Osvyannikova IG, Hralambieva IH, et al. Multigenic control of measles vaccine immunity by polymorphisms in measles receptor, innate pathway, and cytokine genes. Vaccine 2012; 30: 2159.
81. Raghavaiah S, Stegall MD. New therapeutic approaches to antibody-mediated rejection in renal transplantation. Clin Pharmacol Ther 2011; 90: 310.